Drug Profile

PYX 202 - Pyxis Oncology

Alternative Names: anti-DLK1 ADC; DLK1-MMAE; LCB-67; LCB14-15XX - LigaChem Biosciences/Y-Biologics; MMAE-anti-DLK1; PYX-202 - Pyxis Oncology

Latest Information Update: 08 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator LegoChem Biosciences
Developer LigaChem Biosciences; Pyxis Oncology
Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
Mechanism of Action Apoptosis inhibitors; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

21 Sep 2022 Early research in Solid tumours in South Korea (Parenteral) (LegoChem Biosciences pipeline, September 2022)
15 Aug 2022 Discontinued - Preclinical for Solid tumours in USA (Parenteral)
27 Apr 2021 Pyxis Oncology announces intention to submit IND, by the end of 2022

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com